Loxo Oncology and fellow Stamford biotech firm Cara Therapeutics have benefited from increasing investor confidence in their work. This year, the two enterprises have cumulatively attracted hundreds of millions of dollars to support their operations.

Their records show biopharmaceutical businesses’ enduring ability to tap into large amounts of capital — if they have the scientific results to prove their progress.​